tetano
Editor, Senior Moderator
Virus Res. 2016 Aug 3. pii: S0168-1702(16)30274-X. doi: 10.1016/j.virusres.2016.07.010. [Epub ahead of print]
[h=1]Immunogenicity and protective efficacy of recombinant fusion proteins containing spike protein of infectious bronchitis virus and hemagglutinin of H3N2 influenza virus in chickens.[/h] Yin L[SUP]1[/SUP], Zeng Y[SUP]1[/SUP], Wang W[SUP]2[/SUP], Wei Y[SUP]1[/SUP], Xue C[SUP]1[/SUP], Cao Y[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Infectious bronchitis (IB) is an acute and highly contagious viral respiratory disease of chickens and vaccination is the main method for disease control. The S1 protein, which contains several virus neutralization epitopes, is considered to be a target site of vaccine development. However, although protective immune responses could be induced by recombinant S1 protein, the protection rate in chickens was still low (<50%). Here, we generated fused S1 proteins with HA2 protein (rS1-HA2) or transmembrane domain and cytoplasmic tail (rS1-H3(TM)) from hemagglutinin of H3N2 influenza virus. After immunization, animals vaccinated with fusion proteins rS1-HA2 and rS1-H3(TM) demonstrated stronger robust humoral and cellular immune responses than that of rS1 and inactivated M41 vaccine. The protection rates of groups immunized with rS1-HA2 (87%) were significantly higher than the groups inoculated with rS1 (47%) and inactivated M41 vaccine (53%). And chickens injected with rS1-H3(TM) had similar level of protection (73%) comparing to chickens vaccinated with rS1 (47%) (P=0.07). Our data suggest that S1 protein fused to the HA2 or TM proteins from hemagglutinin of H3N2 influenza virus may provide a new strategy for high efficacy recombinant vaccine development against IBV.
Copyright ? 2016. Published by Elsevier B.V.
[h=4]KEYWORDS:[/h] Fusion proteins; H3N2; IBV; Immunogenicity; S1 protein
PMID: 27497621 DOI: 10.1016/j.virusres.2016.07.010
[PubMed - as supplied by publisher]
[h=1]Immunogenicity and protective efficacy of recombinant fusion proteins containing spike protein of infectious bronchitis virus and hemagglutinin of H3N2 influenza virus in chickens.[/h] Yin L[SUP]1[/SUP], Zeng Y[SUP]1[/SUP], Wang W[SUP]2[/SUP], Wei Y[SUP]1[/SUP], Xue C[SUP]1[/SUP], Cao Y[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Infectious bronchitis (IB) is an acute and highly contagious viral respiratory disease of chickens and vaccination is the main method for disease control. The S1 protein, which contains several virus neutralization epitopes, is considered to be a target site of vaccine development. However, although protective immune responses could be induced by recombinant S1 protein, the protection rate in chickens was still low (<50%). Here, we generated fused S1 proteins with HA2 protein (rS1-HA2) or transmembrane domain and cytoplasmic tail (rS1-H3(TM)) from hemagglutinin of H3N2 influenza virus. After immunization, animals vaccinated with fusion proteins rS1-HA2 and rS1-H3(TM) demonstrated stronger robust humoral and cellular immune responses than that of rS1 and inactivated M41 vaccine. The protection rates of groups immunized with rS1-HA2 (87%) were significantly higher than the groups inoculated with rS1 (47%) and inactivated M41 vaccine (53%). And chickens injected with rS1-H3(TM) had similar level of protection (73%) comparing to chickens vaccinated with rS1 (47%) (P=0.07). Our data suggest that S1 protein fused to the HA2 or TM proteins from hemagglutinin of H3N2 influenza virus may provide a new strategy for high efficacy recombinant vaccine development against IBV.
Copyright ? 2016. Published by Elsevier B.V.
[h=4]KEYWORDS:[/h] Fusion proteins; H3N2; IBV; Immunogenicity; S1 protein
PMID: 27497621 DOI: 10.1016/j.virusres.2016.07.010
[PubMed - as supplied by publisher]